Management Team

Liren Tang
PhD, Chief Executive Officer and President

Dr. Liren Tang has been the President and CEO of the Company since November 2009. From 2007-2009, as the Director of Clinical Development at the Company, Liren led a clinical research team to the successful completion of multiple clinical trials. With the compelling clinical data, the Company reached a successful partnering agreement for it’s lead immunology drug program (WBI-1001) with GlaxoSmithKline (GSK) for a total price of up to $230 million dollars in the year 2012. Prior to joining Welichem, Liren was a principal or co-principal investigator at the Vancouver Coastal Health Research Institute for diverse scientific and clinical research projects addressing various aspects of inflammatory diseases and cancers. He is an author of over 30 peer-reviewed scientific publications. Liren received his PhD in Cell and Developmental Biology at the University of British Columbia.